Streetbeat News

Analyst Ratings

MPC

Marathon Petroleum (NYSE:MPC) has received various analyst ratings in the last quarter, with 2 bullish, 5 somewhat bullish, and 4 indifferent. The company's average price target has increased by 7.59% from the previous average price target of $138.91 to $149.45.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

BJ

Over the past 3 months, 6 analysts have published their opinion on BJ's Wholesale Club (NYSE:BJ) stock. The analysts have an average price target of $75.33 versus the current price of BJ's Wholesale Club at $66.45, implying an upside. This current average represents a 4.44% decrease from the previous average price target of $78.83.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

PGY

Pagaya Techs (NASDAQ:PGY) has received 7 analyst ratings in the last quarter, with 4 being bullish, 2 somewhat bullish, and 1 indifferent. The average price target is $4.46, indicating a potential upside from the current price of $2.2472. This average has increased by 105.53% from the previous average price target of $2.17.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:00 pm

LNW

SCPL

Truist Securities analyst Barry Jonas has reiterated a Buy rating on Light & Wonder, Inc. (NASDAQ:LNW), raising the price target to $86 from $78. This follows a robust Q2 beat and the expected acquisition of SciPlay Corporation (NASDAQ:SCPL) in Q4. Despite industry headwinds, SciPlay continues to see growth. LNW's management also reiterated its $1.4 billion 2025 AEBITDA target, citing expansion into adjacent markets and attracting top game design talent as key contributors.

Portfolio Pulse from Nabaparna Bhattacharya

September 08, 2023 | 6:54 pm

ADBE

Barclays analyst Saket Kalia maintains an Equal-Weight rating on Adobe (NASDAQ:ADBE) and raises the price target from $540 to $620.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 6:54 pm

ZVSA

HC Wainwright initiated coverage on ZyVersa Therapeutics Inc (NASDAQ:ZVSA) with a Buy Rating and a price target of $2.50. Despite the stock's steady decline since its IPO, the analyst believes ZyVersa has the potential to build significant stockholder value. The company's initial VAR 200 data in diabetic kidney disease patients in 2Q24 is eagerly anticipated and expected to validate the asset and potentially improve both investor sentiment and ZVSA shares.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 6:52 pm

ATOS

Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ:ATOS) with an Overweight rating and a price target of $5. The analysts believe that the market has underappreciated the potential of ATOS' lead program (Z)-endoxifen, a promising new selective estrogen receptor modulator (SERM) for breast cancer treatment. They expect positive data readouts to drive upward earnings estimate revisions and ATOS' stock higher.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 6:47 pm

DE

A large bearish position has been taken on Deere (NYSE:DE), with 29 uncommon options trades spotted, the majority of which are puts. The sentiment of these big-money traders is split between 41% bullish and 58% bearish. The price of DE is currently down -2.75% at $400.4. Analysts from Oppenheimer, Deutsche Bank, JP Morgan, Stifel, and Credit Suisse have maintained their ratings on Deere, with price targets ranging from $380 to $551.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 6:45 pm

CHPT

RBC Capital Markets analyst Chris Dendrinos initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT) with an Outperform rating and a price target of $9. Dendrinos sees CHPT as the market leader in level 2 charging solutions in the U.S. with a 45% market share. The analyst is bullish on CHPT's strategy and believes it is well positioned to capitalize on the opportunity from EV adoption rates and charging infrastructure demand. CHPT shares are trading lower by 8.5% at $5.76.

Portfolio Pulse from Lekha Gupta

September 08, 2023 | 6:37 pm

BAC

GILD

Shares of Gilead Sciences, Inc (NASDAQ:GILD) are trading higher, bolstered by Bank of America Securities' bullish outlook on the stock. The bank highlighted growth avenues within Gilead's core HIV segment and ventures into hematology/oncology. Analyst Geoff Meacham upgraded the stock from Neutral to Buy, raising the price target from $88 to $95. He identified Gilead's HIV endeavors, especially its next-generation asset, Lenacapavir, as a key growth driver. The bank also noted optimistic moves in hematology and oncology, powered by drugs like Trodelvy and Kite.

Portfolio Pulse from AJ Fabino

September 08, 2023 | 6:31 pm